Follow the latest updates of the聽outbreak聽on our聽timeline.
US-based immunology company has identified two monoclonal antibodies (mAbs) that can bind to the new coronavirus, 2019-nCoV or SARS-CoV-2.
The company discovered the antibodies from an existing library of 20 fully human antibodies, which bind and neutralise certain coronaviruses.
Researchers formerly identified these coronavirus antibodies to attach to and neutralise SARS coronavirus (SARS-CoV).
The company notes that the antibodies act on the SARS-CoV-2 spike protein present in the region used by the virus to enter cells via the cellular receptor ACE2.
Infection caused by the new coronavirus has been聽officially named听颁辞惫颈诲-19.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataVir Biotechnology CEO George Scangos said: 鈥淲e are in the process of assessing neutralisation with a pseudo-virus. In addition, we are working with international partners to assess the capacity of these antibodies to neutralise the live virus, SARS-CoV-2.鈥�
The company is exploring if these mAbs, or other antibodies identified, can offer effective treatment or prophylaxis against the virus.
Vir intends to form alliances with companies and governmental agencies to support its research and to access manufacturing capacity worldwide.
Vir Biotechnology chief scientific officer Herbert Virgin said: 鈥淲e are pleased that, using the same platform that was used to isolate mAb114, which has proven to be active against Ebola, we have quickly identified antibodies with potential biological activity against SARS-CoV-2.鈥�
According to the company, antibodies can be both therapeutic and prophylactic, while vaccines provide only protection.
An antibody delivers an immune response that becomes effective within hours of injection, while vaccine involves making of an immune response by an individual and takes weeks.
Last month, Vir announced that the company is using different platforms to determine if its previously identified mAbs against coronavirus can bind and neutralise the virus.
The company is using its antibody technology platform to isolate new antibodies specific for SARS-CoV-2.
